异动解读 | 丹纳赫上调全年盈利预期,盘前大涨5.29%

异动解读
Jul 23

7月23日周三,生命科学公司丹纳赫(Danaher,股票代码:DHR)股价在盘前交易中大涨5.29%,引发市场关注。这一涨幅主要源于公司上调了年度盈利预期,以及分析师们对公司前景的积极评价。

据悉,丹纳赫上调全年盈利预期主要得益于其制药客户对生物加工的稳定需求以及中国经济的复苏。多家券商对丹纳赫的表现给予了积极评价。摩根大通维持"增持"评级,目标价为260美元,认为丹纳赫强大的产品组合能够抵御宏观压力。富国银行表示,生物加工行业继续呈现稳健复苏,而生命科学领域将在下半年有所改善。巴克莱银行预计,如果生物加工需求回升,2026年该公司业务的核心增长率将达到5%-6%。

值得注意的是,同行企业赛默飞世尔科技(Thermo Fisher Scientific)也于同日公布了超出预期的季度业绩,其股价在盘前交易中上涨2.5%。赛默飞的强劲表现进一步印证了生命科学行业的整体向好趋势,这可能也为丹纳赫股价的上涨提供了额外支撑。分析人士认为,随着生物加工需求的持续增长和中国市场的复苏,丹纳赫有望在未来继续保持良好的增长势头。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10